newsfilter
← Latest News
Business Wire·

Reata Pharmaceuticals Completes Rolling Submission of New Drug Application for Omaveloxolone for the Treatment of Patients with Friedreich's Ataxia

If Approved, Omaveloxolone Would Become the First Therapy Indicated for the Treatment of Patients with Friedreich's Ataxia Friedreich's Ataxia Affects Approximately 5,000 Patients in the United States with an Estimated 4,000 Diagnosed Patients Rea